Nordea repeats its Buy rating on healthcare and diagnostics company Medicover but lowers the price target to 340 kronor from 350 kronor after the third-quarter report.
The bank lowers its forecasts for adjusted EBITDA in 2026–2028 by 1–2 percent following weaker growth and continued reimbursement pressure in Germany. At the same time, margins are improving and Nordea expects higher volumes in 2027.
The sale of the operations in India strengthens acquisition capacity and provides additional upside beyond the bank’s forecasts.
